Profile
ACGN VRTX REGN SGEN ALNY ARGX
Company Name Aceragen, Inc. Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. Alnylam Pharmaceuticals, Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $3.24M $130.72B $58.75B $43.15B $35.25B $34.28B
Employees 0.03K 6.10K 15.11K 3.26K 2.23K 1.60K
CEO Mr. John C. Taylor Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Dr. Yvonne L. Greenstreet M.B.A., M.D. Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
Ratings
ACGN VRTX REGN SGEN ALNY ARGX
Quant Rating Score 2 4 3 1 3
Quant Rating Sell Buy Neutral Strong Sell Neutral
Trading
ACGN VRTX REGN SGEN ALNY ARGX
Last Close $0.3849 $485.89 $549.28 $228.74 $230.5 $587.59
High 52 $0.38 $516.74 $1201.76 $228.74 $296.75 $671.75
Low 52 $0.38 $392.81 $546.39 $228.74 $143.31 $356.01
Price vs. 52 Week High 1.29 % -5.97 % -54.29 % 0 % -22.33 % -12.53 %
Price vs. 52 Week Low 1.29 % 23.7 % 0.53 % 0 % 60.84 % 65.05 %
Total Return
ACGN VRTX REGN SGEN ALNY ARGX
1 Month Return 0 % -5.42 % -18.95 % 0 % -8.97 % -4.33 %
3 Month Return 0 % 15.14 % -19.41 % 0 % -6.4 % -8.26 %
6 Month Return 0 % -2.58 % -44.96 % 0 % -22.31 % 8.15 %
9 Month Return 0 % -0.51 % -49.4 % 0 % -3.97 % 26.8 %
YTD Return 0 % 20.66 % -22.89 % 0 % -2.04 % -4.46 %
1 Year Return 0 % 23.6 % -39.05 % 0 % 58.62 % 60.46 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACGN VRTX REGN SGEN ALNY ARGX
Dividend Yield Percentage (TTM) - - 0.16 % - - -
Dividend Paid and Capex Coverage Ration (TTM) - -1.65 % 5.37 % -2.27 % -0.24 % -44.32 %
Dividend Per Share (TTM) - - 0.88 % - - -
Payout Ratio (TTM) - - - - - -
Growth
ACGN VRTX REGN SGEN ALNY ARGX
Asset Growth 190 % -0.87 % 14.15 % -1.21 % 10.71 %
Gross Profit Growth - 10.25 % 8.23 % 22.93 % 26.81 %
Revenue Growth - 11.66 % 8.27 % 24.65 % 22.97 %
Revenue 3 Year 73.11 % 45.6 % -13.44 % 91.56 % 145.29 %
Revenue 5 Year 91.54 % 163.93 % 82.78 % 215.48 % 769.33 %
Revenue 10 Year 494.86 % 1632.15 % 429.43 % 494.04 % 2468.51 %
EBIT Growth -0.52 % -105.41 % -1.39 % 10.13 % 37.31 %
Net Income Growth -123.81 % -114.8 % 11.61 % 9.51 % 36.82 %
Net Income 3 Yeari Growth Per Share 78.69 % -122.89 % -46.47 % -763.59 % 69.96 %
Net Income 5 Yeari Growth Per Share 87.42 % -145.38 % 111.07 % -276.93 % 73.33 %
Net Income 10 Yeari Growth Per Share 92.42 % 33.84 % 1232.49 % -624.16 % 55.42 %
Operating Income Growth -0.52 % -105.41 % -1.39 % 10.13 % 37.31 %
Operating Cash Flow Growth (CFG) 0.41 % -113.93 % -3.78 % 9.07 % -107.98 %
Operating 3 Year CFG 71.62 % -118.65 % -38.85 % -147.99 % 98.81 %
Operating 5 Year CFG 84.25 % -131.3 % 84.11 % -195.86 % 97.46 %
Operating 10 Year CFG 92.33 % 12.43 % 517.51 % -2622.09 % 97.1 %
EPS Growth -121.42 % -114.8 % 10.39 % 10.81 % 38.64 %
EPS Diluted Growth 26.69 % -114.97 % 10.27 % 10.81 % 38.64 %
Book Value Per Share 17.52 % -6.59 % 11.76 % -9.83 % 129.53 %
Share Holder 3 Year Equity Growth Per Share 279.73 % 62.6 % 53.21 % 33.72 % -89.49 %
Share Holder 5 Year Equity Growth Per Share -87.15 % 168.85 % 167.88 % 220.81 % -96.04 %
Share Holder 10 Year Equity Growth Per Share -63.34 % 1265.7 % 1113.59 % 691.19 % -95.86 %
Dividend Per Share Growth - - - - -
Dividend 3 Year Growth Per Share - - - - -
Dividend 5 Year Growth Per Share - - - - -
Dividend 10 Year Growth Per Share -100 % - - - -
Debt Growth -26.12 % 116.42 % 0.06 % -23.28 % -51.69 %
Free Cash Flow Growth 0.41 % -124.1 % -0.08 % 3.67 % -201.54 %
Updated On 31 Dec 2022 31 Dec 2024 31 Dec 2024 31 Dec 2022 31 Dec 2024
Profitability
ACGN VRTX REGN SGEN ALNY ARGX
Gross Profit Margin TTM 100 % 86.09 % 84.47 % 72.37 % 85.62 % 46.33 %
Return on Assets TTM -23.1 % -2.38 % 11.69 % -11.76 % -6.56 % 13.45 %
Return on Equity TTM -68.32 % -3.28 % 14.77 % -16.53 % 905.33 % 16.83 %
Return on Capital Employed TTM -34.91 % -1.3 % 10.89 % -16.87 % -5.79 % -0.31 %
Net Income Per EBT TTM 78.71 % -215.53 % 92.32 % 100.55 % 73.71 % 25990.14 %
EBT Per Ebit TTM 106.69 % -100.69 % 118.85 % 94.01 % 213.34 % -18.79 %
EBIT Per Revenue TTM -572.15 % -2.24 % 28.32 % -36.09 % -7.87 % -0.77 %
Cash Flow To Debt Ratio TTM -4374.11 % -28.16 % 222.76 % -185.98 % -0.64 % -201.37 %
Receivables Turnover TTM 1.16 6.84 2.29 1.98 5.55 2.46
Payables Turnover TTM - 3.71 2.79 1.54 3.66 1.83
Inventory Turnover TTM - 1.27 0.71 0.65 4.12 2.93
Fixed Asset Turnover TTM 893.75 % 425.82 % 308.76 % 256.83 % 323.99 % 5106.8 %
Asset Turnover TTM 4.81 % 48.84 % 37.61 % 34.46 % 53.02 % 35.83 %
Operating Cash Flow Per Share TTM -7.52 -1.91 41.08 -1.12 -0.06 -1.07
Free Cash Flow Per Share TTM -7.52 -3.07 33.43 -1.62 -0.33 -1.09
Cash Per Share TTM 369.79 % 2375.11 % 16647.4 % 657.5 % 2095.42 % 4597.04 %
Operating Cash Flow Sales Ratio TTM -503.81 % -4.48 % 31.13 % -16.85 % -0.37 % -3.54 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 160.43 % 81.38 % 144.14 % 512.38 % 102.26 %
Cash Flow Coverage Ratios TTM -4374.11 % -28.16 % 222.76 % -185.98 % -0.64 % -201.37 %
Price To Free Cash Flows Ratio TTM -0.13 -165.4 16.33 -141.85 -827.74 -444.85
Price To Operating Cash Flows Ratio TTM -0.05 -266.09 13.37 -203.89 -4192.79 -531.16
Price Cash Flow Ratio TTM -0.05 -266.09 13.37 -203.89 -4192.79 -531.16
Income Statement (TTM)
ACGN VRTX REGN SGEN ALNY ARGX
Revenue $0B $11.02B $14.2B $1.96B $2.25B $2.19B
Gross Profit $0B $9.49B $12.23B $1.55B $1.92B $1.96B
Gross Profit Ratio 100% 86.11% 86.13% 79.1% 85.62% 89.62%
EBITDA $-0.01B $0.49B $5.32B $-0.62B $-0.18B $0B
Net Income $-0.02B $-0.54B $4.41B $-0.61B $-0.28B $0.83B
EPS Diluted -7.17 -2.08 38.34 -3.3 -2.16 12.78
Balance Sheet (MRQ)
ACGN VRTX REGN SGEN ALNY ARGX
Long Term Debt $0B $1.66B $2.7B $0.04B $0B $0.03B
Total Liabilities $0.06B $6.12B $8.41B $0.87B $4.17B $0.68B
Total Equity $0.04B $16.41B $29.35B $2.8B $0.07B $5.31B
Total Investments $0B $6.65B $6.52B $1.42B $1.73B $1.82B
Total Debt $0B $1.75B $2.7B $0.04B $1.3B $0.04B
Total Assets $0.1B $22.53B $37.76B $3.67B $4.24B $5.99B
Cash Flow Statement (TTM)
ACGN VRTX REGN SGEN ALNY ARGX
Net Income $-0.02B $-0.54B $4.41B $-0.61B $-0.28B $0.8B
Inventory $0B $-0.52B $-0.62B $-0.23B $0.01B $-0.09B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.02B $-0.49B $4.42B $-0.45B $-0.01B $-0.08B
Capital Expenditure $0B $-0.3B $-0.76B $-0.08B $-0.03B $-0B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 18.66
ABCL AbCellera Biologics Inc. 2.415
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 4.89
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 0.8871
ABPWW 0.0465
ABSI Absci Corporation 3.05
ABUS Arbutus Biopharma Corporation 3.015
ABVC ABVC BioPharma, Inc. 0.86
ABVX Abivax SA American Depositary Shares 6.26
ACAD ACADIA Pharmaceuticals Inc. 14.64
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.5655
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 2.02
ACIU AC Immune SA 1.5
ACLX Arcellx, Inc. 60.99
ACRV Acrivon Therapeutics, Inc. Common Stock 1.755
ETFs With Exposure to ACGN
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 260.14
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 115.463
VXF Vanguard Extended Market Index Fund 0 162.38
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 121.91
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 121.92
VEMPX Vanguard Extended Market Index InstlPlus 0 300.86
Unlock